A Phase 1 interventional study of Social Management Training in Sex Chromosome Disorders, sponsored by University of Oslo. Recruiting at 1 site in Norway. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by University of Oslo · Phase 1, Interventional, and Treatment
We will examine is Social Management Training, a 10-session group-based psychosocial intervention will improve the primary outcome mental health, and secondary outcomes executive functions and autism symptoms, in a multiple baseline design with 3 pre-measurement points and 3 post-measurement points spanning 30 weeks, including the 10 weeks of intervention. Participants will be adults (16-65 years) with sex chromosome aneuploidies.
Background: Persons with sex chromosome aneuploidies (SCAs, i.e., a number of sex chromosomes that is different from the most common 46,XX and 46,XY), often struggle with social interactions. A Dutch pilot study examined Social Management Training (SMT), an intervention designed to help people develop their abilities to navigate interactions with others in men with Klinefelter syndrome (KS; 47,XXY). SMT was adapted to target executive functions, emotion regulation, and social cognition in a novel neurocognitive-behavioral program tailored to the specific vulnerabilities of men with KS, and showed promising outcomes. The current study aims to expand on the Dutch pilot study by (1) Adapting SMT to Norwegian individuals with SCAs in an online-delivered format enabling wide geographic reach; (2) Testing the feasibility, acceptability, and potential benefits of SMT; and (3) Examine the use of SMT on SCAs beyond KS. Methods: The intervention comprises 10 group sessions. Through a single-group multiple baseline design, measures are collected at six time points; three pre- and three post-intervention. The main effect to be examined is the difference between pre- and post-intervention. The primary outcome is mental health, and the secondary outcomes are social and executive functioning. Participants are recruited through the Norwegian National Center for Rare Diseases, the Norwegian Klinefelter association, and endocrinologists. We plan to include 20-30 participants by the end of 2028. Discussion: SMT aims to evaluate the feasibility of a digitally based psychosocial intervention designed to improve mental health, as well as social, emotional and executive functioning among individuals with SCAs. The findings will inform intervention refinement and the design of a future definitive randomized controlled trial. The development of such interventions can lead to socio-economic benefits in the form of long-term improved health outcomes for people by improving overall functioning.
47 studies on the registry are indexed under Klinefelter Syndrome; 17 are open to participants now.
This study's planned enrollment of 30 is below the median of 44 across 19 interventional studies indexed under Klinefelter Syndrome.
Browse Klinefelter Syndrome studies →University of Oslo is the lead sponsor of 177 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The inclusion criteria are: (a) Proficiency in a Scandinavian language. Participants must state that they have satisfactory skills to participate in group discussions, and answer questionnaires in Norwegian; (b) Age 16 to 69 years. The age range is set to include adults of the age of consent for participation in health research. The upper age limit was set to prevent measurements from being affected by age-related factors; (c) Access to a computer (or smartphone) with internet connection - but note that we can lend a computer to participants who may require this; (d) Genetically confirmed SCA. Participants provide medical confirmation of diagnosis, unless participants are recruited via Frambu (where medical confirmation is available in the user registry for KS 47,XXY karyotype; Jacobs 47,XYY karyotype; Triple X, 47,XXX karyotype; and Turner 45,X karyotype).
There are no explicit exclusion criteria. Ongoing assessments are made during eligibility screening and when conducting training program regarding appropriateness of the training program, both individually and in groups. If the group leader becomes aware of information that indicates the need for specialist health services (e.g., indication of severe mental illness or acute suicidality), this is handled on a case-by-case basis, and the person concerned is then put in contact with the appropriate health care services.
-
A 10.-session psychosocial digital group intervention
Behavioral: Social Management Training
The 10 sessions focus on (1) Introduction and learning targets; (2) Information processing in a social context; (3) Attention and emotions in a social context; (4) Inhibition and emotions in a social context; (5) Flexibility and planning in a social context; (6) Working memory in a social context; (7) Parent/friend/partner session; (8\&9) Individual learning targets; (10) Summary/Integration
Symptom Checklist 25 (SCL-25)
The SCL-25 is a 25 item measure of mental health that compiles into an anxiety and a depression dimension (compared to nine dimensions in the full 90-item version).
Time frame: Measured three times during 8 weeks prior to the intervention and then three times during 8 weeks after the intervention
The Social Responsiveness Scale - Second edition (SRS-2).
The SRS-2 is a 65-item measure of social impairments associated with autism spectrum disorders
Time frame: Measured three times during 8 weeks prior to the intervention and three times during 8 weeks after the intervention
Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A).
The BRIEF-A is a 75-item measure of executive and self-regulation in everyday situations for adults
Time frame: Measured three times during 8 weeks prior to the intervention and three times during 8 weeks after the intervention
Plan to share: No — The samples are very small since these disorders are rare, so they are too easily identifiable
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Sep 2029, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.